And Roche gets a novel and one of the most advanced clinical candidates for the treatment of obesity that it can combine with its existing obesity candidates. Petrelintide is an amylin analog that ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.

Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival ...

But while analysts saw Roche as an early contender for petrelintide, both firms insisted it was by no means a done deal. "It was a very competitive process, with a number of parties until the end ...